Bergamottin

Bergamottin is a natural furanocoumarin found predominantly in grapefruit juice and bergamot orange peel that exerts anticancer and enzyme-inhibitory effects. Its primary mechanism involves irreversible inhibition of cytochrome P450 3A4 (CYP3A4) in intestinal enterocytes, which significantly alters the bioavailability of numerous pharmaceutical drugs.

Origin & History

Bergamottin is a natural furanocoumarin found primarily in grapefruit and bergamot. It is extracted from the juice and peel of these citrus fruits, typically through juice processing or solvent extraction methods.

Historical & Cultural Context

Bergamottin itself has no documented historical or traditional uses; it is primarily a component of grapefruit juice, which is traditionally consumed for its nutritional and flavor properties.

Health Benefits

• Inhibits migration and invasion of glioma cells by inactivating Rac1 and downregulating MMP-9 (in vitro study, PMID: 29435067). • Induces apoptosis and G2/M arrest in lung cancer cells, though findings are limited to preclinical data (retracted study, PMID: 27222242). • Modulates miR-145/Cyclin D1 axis to inhibit melanoma growth, based on preclinical mouse studies. • Inhibits CYP3A4, increasing bioavailability of certain drugs like felodipine by up to 40% (preclinical and clinical context, no specific study cited). • Abrogates STAT3 activation in multiple myeloma cells, enhancing apoptosis (animal studies, PMID: not in excerpt).

How It Works

Bergamottin acts as a mechanism-based, irreversible inhibitor of the CYP3A4 enzyme by forming a reactive intermediate that covalently binds to the enzyme's active site, effectively blocking first-pass metabolism of many drugs in intestinal epithelial cells. In preclinical cancer models, it suppresses glioma cell migration by inactivating the Rho GTPase Rac1 and downregulating matrix metalloproteinase-9 (MMP-9), disrupting the cytoskeletal remodeling required for invasion. Additionally, it modulates the miR-145/Cyclin D1 axis, inducing G2/M cell cycle arrest and promoting apoptosis in lung and other cancer cell lines via mitochondria-mediated caspase activation.

Scientific Research

There are no human clinical trials or meta-analyses for bergamottin; research is limited to in vitro and animal studies. For example, a study on glioma cells (PMID: 29435067) showed inhibited cell migration, and a retracted mouse study (PMID: 27222242) initially reported tumor weight reduction.

Clinical Summary

The vast majority of bergamottin research is preclinical, conducted in vitro using human cancer cell lines (glioma, lung, breast) or in animal pharmacokinetic models, with no robust human clinical trials specifically on isolated bergamottin supplementation to date. In vitro studies, such as PMID 29435067, demonstrated inhibition of glioma cell migration and invasion, though these findings have not been replicated in human subjects. Notably, at least one cited study on its apoptotic effects in lung cancer cells (PMID 27222242) has been retracted, substantially weakening the evidence base in that area. Its drug-interaction effects via CYP3A4 inhibition are the best-characterized pharmacological action and are supported by well-replicated pharmacokinetic data from grapefruit juice interaction studies.

Nutritional Profile

Bergamottin is a natural furanocoumarin compound, not a food ingredient with conventional macronutrient or micronutrient content. It is a lipophilic secondary metabolite primarily classified as a bioactive phytochemical. Key compositional data: Bergamottin (5-geranyloxy-7-methoxycoumarin, CAS 7380-40-7) is found in grapefruit juice at approximate concentrations of 2–23 mg/L in fresh grapefruit juice, with higher concentrations in the peel oil (estimated 0.5–1.5 mg/g in grapefruit peel extract). It is also present in bergamot essential oil (Citrus bergamia) at trace-to-moderate levels, as well as in pomelo and certain lime varieties. As a furanocoumarin, it contains no meaningful caloric value, protein, fat, carbohydrate, fiber, vitamins, or minerals in the quantities typically encountered. Its primary characterization is as a potent irreversible inhibitor of cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, with an IC50 for CYP3A4 inhibition reported at approximately 0.16–0.8 µM in vitro. Bioavailability is limited due to its lipophilic nature (logP approximately 4.5); oral absorption is moderate, with rapid first-pass metabolism. It is typically encountered as a minor constituent within whole grapefruit products rather than as an isolated nutritional compound, and dietary intake from normal grapefruit consumption ranges from approximately 1–20 mg per serving depending on preparation method and cultivar.

Preparation & Dosage

Preclinical studies used IP doses of 25-100 mg/kg in animal models. Oral doses of 6-12 mg have been noted to increase felodipine bioavailability in human contexts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Grapefruit extract, bergamot oil, felodipine, other furanocoumarins, antioxidant-rich foods

Safety & Interactions

Bergamottin's most clinically significant safety concern is its potent inhibition of intestinal CYP3A4, which can dramatically increase plasma concentrations of drugs such as statins (simvastatin, atorvastatin), calcium channel blockers (felodipine), immunosuppressants (cyclosporine), and certain benzodiazepines, raising the risk of toxicity. Individuals taking any CYP3A4-metabolized medication should avoid bergamottin-containing supplements or high-volume grapefruit juice consumption without physician guidance. Phototoxicity is a known class effect of furanocoumarins; topical exposure combined with UV radiation can cause skin burns and hyperpigmentation. Safety data during pregnancy and lactation are absent, and supplemental use should be avoided in these populations as a precautionary measure.